Why it suddenly seems like every celebrity has their own mobile network
Celebrities have long put their names on everything from shoes to cosmetics to snacks. Now, they're attaching their brand to mobile phone networks.
Trump Mobile, announced on Monday, is the latest cellular service pegged to a high-profile figure, joining the likes of wireless services from actors such as Jason Bateman and Ryan Reynolds. Major carriers are no longer the only ones cashing in on the airwaves that power the devices in our pockets. Comedians, sports teams and retailers have launched their own mobile networks as the technology has become more accessible to companies outside the telecoms sp
Instead of building their own networks, these providers — known as mobile virtual network operators (MVNOs) — lease spectrum from major carriers like Verizon, AT&T and T-Mobile. That makes it easier for anyone to launch their own network so long as they can buy the bandwidth to power it, while providing another way for major carriers to monetize their networks.
MVNO networks aren't new; Virgin Group founder and entrepreneur Richard Branson launched Virgin Mobile – an MVNO – in 1999. But the recent wave of celebrity-fronted MVNOs likely stems from a couple of trends: a decrease in loyalty to major carriers; technology that facilitates business operations like customer support and billing; and the prevalence of electronic SIM cards that make it easier for consumers to switch plans and carrier services.
Consumers are more faithful to their phones than they are to their carriers, said Michael Levin, an analyst with Consumer Intelligence Research Partners, a firm that studies consumer behavior in the mobile carrier market. That could explain why customers are willing to ditch their legacy carrier for something new.
'The technology made it a little easier to switch. And at the same time, consumers became a lot more loyal to the phone manufacturer,' he said. 'And then the carrier was kind of less important.'
Trump Mobile, like other MVNOs, is pitching itself as a more accessible alternative to the big three carriers, Verizon, AT&T and T-Mobile. For $47.45 a month (plus applicable taxes and fees), subscribers get unlimited data, talk and texting, although data speeds are slowed after the first 20GB. Telehealth services and roadside assistance are also included.
'A big part of what we've done … has been focused on technology for people who have been underserved, whether that's been in crypto or anything else, but one of the places where we felt there was lackluster performance was in the mobile industry,' Donald Trump Jr. said an event at Trump Tower in New York on Monday.
The launch comes after actors Jason Bateman, Will Arnett and Sean Hayes last week launched a mobile service called SmartLess Mobile, named after the trio's popular podcast. SmartLess Mobile is intended to provide cheap capped data plans for consumers, since many people spend most of their time on Wi-Fi networks, SmartLess Mobile CEO Paul McAleese previously told CNN.
'Deadpool' actor Ryan Reynolds purchased an ownership stake in MVNO Mint Mobile in 2019. He's been the face of the network since then, even though T-Mobile bought the carrier for $1.35 billion in 2023.
While AT&T, Verizon and T-Mobile are the dominant players in the US mobile market, there is some data to suggest MVNO networks are growing. Consultancy group Opensignal found that MVNOs are consistently gaining more bring-your-own-device subscribers than they lose, unlike traditional network providers.
Even though plans from MVNOs may not always be cheaper than those from mainstream carriers, they often offer compelling promotions.
'You get this very exciting offer, for example: three months at $15 a month. But thereafter then you go back to $45,' said Octavio Garcia, a senior research analyst at market research firm Forrester. 'But when you are done with three months, there is a new offer that brings you down to $30, not $45.'
These kinds of mobile networks might feel like a relatively new trend in the United States, but they're common abroad, according to Garcia and Runar Bjørhovde, an analyst at market research firm Canalys.
Walmart Mexico's Bait MVNO network, for example, has 19.8 million users, according to the company's first quarter results released in April. In Italy, there's a mobile network branded after the AC Milan soccer team.
There's also been a rise in 'MVNO-in-a-box services,' or companies that provide a package of offerings like electronic SIM distribution, network access and billing to help clients set up their own MVNO networks. These types of services are growing, with Juniper Research estimating that global revenue from MVNO-in-a-box services will surpass $1 billion in 2029.
'To see that it's easier to set up MVNO as a smaller company, I think it's a sign of a telecom industry that's moving in a certain direction,' said Bjørhovde.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on
Yahoo
37 minutes ago
- Yahoo
PGA Tour Sends Strong Scottie Scheffler Message on Saturday
PGA Tour Sends Strong Scottie Scheffler Message on Saturday originally appeared on Athlon Sports. The PGA Tour celebrated Scottie Scheffler in style on Saturday, honoring the world No. 1 golfer on his birthday with an Instagram post from @pgatour showcasing his top 10 career shots. Advertisement The post, shared earlier today, serves as a tribute to his remarkable journey, timed perfectly as fans and the Tour alike mark his special day. This gesture underscores Scheffler's status as a golfing icon and the Tour's commitment to celebrating its brightest stars. The post highlights iconic moments, including his hole-in-one at the 2023 Charles Schwab Challenge and his remarkable eagle hole-out at the 2024 Players Championship. These shots reflect the precision and power that have defined his rise, with three wins in his last five starts this season, including a victory at the 2025 PGA Championship. Scottie Scheffler plays his shot from the tenth tee during the first round.© Charles LeClaire-Imagn Images The birthday tribute aligns with Scheffler being in contention at the Travelers Championship this weekend, tying for the 36-hole lead with a score of nine under par. Advertisement This celebration sends a clear message: Scheffler, at 29, is the Tour's present and future and will continue to dominate a majority of the tournaments he plays in. With competitors like Tommy Fleetwood and Justin Thomas challenging his lead, his career highlights remind fans of his consistency and clutch performances. The post has sparked excitement, reinforcing the Tour's intent to honor excellence while hyping its toughest course setups and merit-based finales. For golf enthusiasts, it's a fitting birthday salute to a player redefining the sport. Related: PGA Tour Teases Scottie Scheffler, Justin Thomas Pairing at Travelers Championship This story was originally reported by Athlon Sports on Jun 21, 2025, where it first appeared.
